免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

国际肿瘤学杂志››2022,Vol. 49››Issue (10): 577-580.doi:10.3760/cma.j.cn371439-20220516-00114

• 一切为了人民健康——我们这十年 •下一篇

免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

张杰^1,², 魏渼倬², 赵玲², 易善永²()

¹新乡医学院研究生院，新乡 453003
²郑州大学附属郑州中心医院肿瘤内科，郑州 450007

收稿日期:2022-05-16修回日期:2022-06-06出版日期:2022-10-08发布日期:2022-12-01
通讯作者:易善永 E-mail:yisy2001@126.com
基金资助:
吴阶平医学基金会临床科研专项资助基金(320.6750.2021-02-142)

Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors

Zhang Jie^1,², Wei Meizhuo², Zhao ling², Yi Shanyong²()

¹Graduate School of Xinxiang Medical University， Xinxiang 453003， China
²Department of Oncology， Zhengzhou Central Hospital Affiliated to Zhengzhou University， Zhengzhou 450007， China

Received:2022-05-16Revised:2022-06-06Online:2022-10-08Published:2022-12-01
Contact:Yi Shanyong E-mail:yisy2001@126.com
Supported by:
Wu Jieping Medical Foundation Clinical Scientific Research Special Fund(320.6750.2021-02-142)

摘要/Abstract

摘要：

目前肿瘤治疗进入了免疫治疗时代。但近年来发现，胸部放疗后应用免疫检查点抑制剂在起到协同抗肿瘤作用的同时，也会引发放射唤醒性肺炎（RRP）。RRP是一种少见的免疫相关不良反应，严重者甚至导致患者死亡。研究免疫检查点抑制剂引起RRP的相关机制以及影响因素，对加强RRP的认知管理以及降低RRP发生风险具有重要意义。

关键词:免疫检查点抑制剂,免疫疗法,放射疗法,肺炎,辐射性肺炎

Abstract:

At present， tumor therapy has entered the era of immunotherapy. However， in recent years， it has been found that the application of immune checkpoint inhibitors after chest radiotherapy can not only play a synergistic anti-tumor effect， but also cause radiation recall pneumonitis （RRP）. RRP is a rare immune-related adverse reaction， which even leads to death in severe cases. It is of great significance to study the mechanisms and influencing factors of RRP caused by immune checkpoint inhibitors for strengthening the cognitive management of RRP and reducing the risk of RRP.

Key words:Immune checkpoint inhibitors,Immunotherapy,Radiotherapy,Pneumonia,Radiation pneumonitis

张杰, 魏渼倬, 赵玲, 易善永. 免疫检查点抑制剂引发放射唤醒性肺炎的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 577-580.

Zhang Jie, Wei Meizhuo, Zhao ling, Yi Shanyong. Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors[J]. Journal of International Oncology, 2022, 49(10): 577-580.

参考文献31

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108. doi:10.1097/CM9.0000000000002108
[2]	Laird J, Leventhal J, Kanowitz J, et al. Radiation recall dermatitis after capecitabine in a patient with triple negative breast cancer[J]. Pract Radiat Oncol, 2021, 11(6): 448-452. DOI: 10.1016/j.prro.2021.06.001. doi:10.1016/j.prro.2021.06.001
[3]	Ye X, Yang J, Stebbing J, et al. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report[J]. BMC Pulm Med, 2022, 22(1): 54. DOI: 10.1186/s12890-022-01846-x. doi:10.1186/s12890-022-01846-xpmid:35123465
[4]	McKay MJ, Foster R. Radiation recall reactions: an oncologic enigma[J]. Crit Rev Oncol Hematol, 2021, 168: 103527. DOI: 10.1016/j.critrevonc.2021.103527. doi:10.1016/j.critrevonc.2021.103527
[5]	McGovern K, Ghaly M, Esposito M, et al. Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review[J]. Future Sci OA, 2019, 5(5): FSO378. DOI: 10.2144/fsoa-2018-0123. doi:10.2144/fsoa-2018-0123
[6]	Cousin F, Desir C, Ben Mustapha S, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer[J]. Radiother Oncol, 2021, 157: 47-55. DOI: 10.1016/j.radonc.2021.01.001. doi:10.1016/j.radonc.2021.01.001pmid:33453313
[7]	Wang YY, Tian XC, Zhu L, et al. Concomitant radiation recall der-matitis and radiation recall pneumonitis induced by pembrolizumab[J]. J Thorac Oncol, 2020, 15(10): e160-e162. DOI: 10.1016/j.jtho.2020.05.014. doi:10.1016/j.jtho.2020.05.014
[8]	Chen Y, Huang Z, Xing L, et al. Radiation recall pneumonitis induced by anti-PD-1 blockade: a case report and review of the literature[J]. Front Oncol, 2020, 10: 561. DOI: 10.3389/fonc.2020.00561. doi:10.3389/fonc.2020.00561pmid:32411597
[9]	Giuranno L, Ient J, De Ruysscher D, et al. Radiation-induced lung injury (RILI)[J]. Front Oncol, 2019, 9: 877. DOI: 10.1186/s12890-020-01376-4. doi:10.3389/fonc.2019.00877pmid:31555602
[10]	Guo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging[J]. Exp Ther Med, 2019, 17(1): 244-250. DOI: 10.3892/etm.2018.6936. doi:10.3892/etm.2018.6936pmid:30651789
[11]	Zhang Z, Zhou J, Verma V, et al. Crossed pathways for radiation-induced and immunotherapy-related lung injury[J]. Front Immunol, 2021, 12: 774807. DOI: 10.3389/fimmu.2021.774807. doi:10.3389/fimmu.2021.774807
[12]	Jia XH, Geng LY, Jiang PP, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors[J]. J Exp Clin Cancer Res, 2020, 39(1): 284. DOI: 10.1186/s13046-020-01749-x. doi:10.1186/s13046-020-01749-x
[13]	Lu L, Sun C, Su Q, et al. Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance[J]. Clin Exp Med, 2019, 19(4): 417-426. DOI: 10.1007/s10238-019-00571-w. doi:10.1007/s10238-019-00571-wpmid:31313081
[14]	Ullah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis[J]. Curr Opin Pulm Med, 2020, 26(4): 321-325. DOI: 10.1097/MCP.0000000000000682. doi:10.1097/MCP.0000000000000682pmid:32427626
[15]	Roy S, Salerno KE, Citrin DE. Biology of radiation-induced lung injury[J]. Semin Radiat Oncol, 2021, 31(2): 155-161. DOI: 10.1016/j.semradonc.2020.11.006. doi:10.1016/j.semradonc.2020.11.006pmid:33610273
[16]	Bukamur H, Katz H, Alsharedi M, et al. Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab[J]. South Med J, 2020, 113(11): 600-605. DOI: 10.14423/SMJ.0000000000001166. doi:10.14423/SMJ.0000000000001166pmid:33140115
[17]	Chen X, Sheikh K, Nakajima E, et al. Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies[J]. Oncologist, 2021, 26(10): e1822-e1832. DOI: 10.1002/onco.13900. doi:10.1002/onco.13900
[18]	Liu Y, Wang W, Shiue K, et al. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer[J]. Radiother Oncol, 2021, 156: 231-238. DOI: 10.1016/j.radonc.2020.10.015. doi:10.1016/j.radonc.2020.10.015
[19]	Shintani T, Kishi N, Matsuo Y, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab[J]. Clin Lung Cancer, 2021, 22(5): 401-410. DOI: 10.1016/j.cllc.2021.01.017. doi:10.1016/j.cllc.2021.01.017pmid:33678582
[20]	Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications[J]. BMC Med, 2020, 18(1): 275. DOI: 10.1186/s12916-020-01718-3. doi:10.1186/s12916-020-01718-3pmid:32943072
[21]	Teng F, Meng X, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review[J]. Cancer Lett, 2018, 414: 166-173. DOI: 10.1016/j.canlet.2017.11.014. doi:S0304-3835(17)30732-2pmid:29155348
[22]	Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radia-tion-induced lung injury: current evidence[J]. BMC Pulm Med, 2021, 21(1): 9. DOI: 10.1186/s12890-020-01376-4. doi:10.1186/s12890-020-01376-4pmid:33407290
[23]	Riemann D, Cwikowski M, Turzer S, et al. Blood immune cell biomarkers in lung cancer[J]. Clin Exp Immunol, 2019, 195(2): 179-189. DOI: 10.1111/cei.13219. doi:10.1111/cei.13219pmid:30246868
[24]	符伶俐, 李萍, 张芮, 等. 胸部肿瘤患者辐射性肺炎的发生和预测因素[J]. 国际肿瘤学杂志, 2020, 47(2): 107-111. DOI: 10.3760/cma.j.issn.1673-422X.2020.02.009. doi:10.3760/cma.j.issn.1673-422X.2020.02.009
[25]	王慧, 夏茸, 魏清雯, 等. 非小细胞肺癌免疫检查点抑制剂相关性肺炎的危险因素及预测生物标志物[J]. 国际肿瘤学杂志, 2021, 48(5): 296-301. DOI: 10.3760/cma.j.cn371439-20210115-00057. doi:10.3760/cma.j.cn371439-20210115-00057
[26]	Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156. DOI: 10.1016/j.lungcan.2018.09.015. doi:S0169-5002(18)30574-9pmid:30429014
[27]	Gomatou G, Tzilas V, Kotteas E, et al. Immune checkpoint inhibitor-related pneumonitis[J]. Respiration, 2020, 99(11): 932-942. DOI: 10.1159/000509941. doi:10.1159/000509941pmid:33260191
[28]	Riviere P, Sumner W, Cornell M, et al. Radiation recall pneumonitis after treatment with checkpoint blockade immunotherapy: a case series and review of literature[J]. Front Oncol, 2021, 11: 662954. DOI: 10.3389/fonc.2021.662954. doi:10.3389/fonc.2021.662954
[29]	Nakamura K, Okubo K, Takahashi T, et al. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma[J]. IJU Case Rep, 2019, 2(1): 30-33. DOI: 10.1002/iju5.12032. doi:10.1002/iju5.12032
[30]	Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab[J]. Cancer Med, 2020, 9(13): 4622-4631. DOI: 10.1002/cam4.3113. doi:10.1002/cam4.3113
[31]	Saito G, Oya Y, Taniguchi Y, et al. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)[J]. Lung Cancer, 2021, 161: 86-93. DOI: 10.1016/j.lungcan.2021.08.019. doi:10.1016/j.lungcan.2021.08.019pmid:34543942